A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)

被引：0
|
作者：
Kittai, Adam
Skarbnik, Alan
Miranda, Miguel
Yong, Alan S. M.
Roos, Jack
Hettle, Robert
Palazuelos-Munoz, Sarah
Shetty, Vikram
Ghia, Paolo
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA
[2] Novant Hlth Canc Inst, Charlotte, NC USA
[3] AstraZeneca, Cambridge, England
[4] AstraZeneca, Wilmington, DE USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] IRCCS Osped San Raffaele, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7540
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Comparative efficacy and safety of ozanimod versus teriflunomide for relapsing-remitting multiple sclerosis: a matching-adjusted indirect comparison
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 140 - 140
  • [42] Matching-adjusted indirect comparison of pirtobrutinib vs. venetoclax continuous monotherapy in patients with relapsed/refractory CLL previously treated with a covalent BTK inhibitor
    Davids, Matthew
    Al-Sawaf, Othman
    Jen, Min-Hua
    Hess, Lisa M.
    Zhang, Jiewen
    Goebel, Benjamin
    Pagel, John M.
    Eyre, Toby A.
    LEUKEMIA & LYMPHOMA, 2023, 64 : S78 - S79
  • [43] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD VERSUS TERIFLUNOMIDE FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    VALUE IN HEALTH, 2020, 23 : S624 - S624
  • [44] Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Nastoupil, Loretta J.
    Bonner, Ashley
    Wang, Pearl
    Almuallem, Lamees
    Desai, Jigar
    Fasan, Omotayo
    Farazi, Thalia
    Kumar, Jinender
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [45] A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 660 - 668
  • [46] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Moreau, Philippe
    Usmani, Saad Zafar
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Delforge, Michel
    Rocafiguera, Albert Oriol
    Nooka, Ajay K.
    Rosinol, Laura
    Bahlis, Nizar J.
    Rodriguez-Otero, Paula
    Martin, Thomas G.
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Krishnan, Amrita Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
    Martin, Tom
    Usmani, Saad Z.
    Schecter, Jordan M.
    Vogel, Martin
    Jackson, Carolyn C.
    Deraedt, William
    Tian, Hong
    Yeh, Tzu-min
    Banerjee, Arnob
    Pacaud, Lida
    Garrett, Ashraf
    Haltner, Anja
    Cameron, Chris
    Van Sanden, Suzy
    Diels, Joris
    Valluri, Satish
    Samjoo, Imtiaz A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1779 - 1788
  • [48] Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
    Bahlis, Nizar J.
    Usmani, Saad Zafar
    Rosinol, Laura
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Rocafiguera, Albert Oriol
    Delforge, Michel
    Garfall, Alfred L.
    Van De Donk, Niels W. C. J.
    Iguez-Otero, Paula Rodr .
    Martin, Thomas G.
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VS BELANTAMAB MAFODOTIN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Moreau, P.
    Usmani, S. Z.
    van de Donk, N. W. C. J.
    Garfall, A. L.
    Delforge, M.
    Oriol, A.
    Nooka, A.
    Rosinol, L.
    Bahlis, N.
    Rodriguez Otero, P.
    Martin, T. G.
    Diels, J.
    Van Sanden, S.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Marshall, A.
    Slavcev, M.
    Londhe, A.
    Krishnan, A.
    VALUE IN HEALTH, 2023, 26 (12) : S5 - S6
  • [50] Efficacy outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
    McGregor, Bradley Alexander
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Rodriguez, Cristina Suarez
    Bourlon, Maria Teresa
    Barata, Pedro C.
    Gulati, Shuchi
    Stwalley, Brian
    Del Tejo, Viviana
    Du, Ella X.
    Wu, Aozhou
    Chin, Andi
    Betts, Keith A.
    Huo, Stephen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345